Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants.
BACKGROUND
Recent studies in animals with experimental respiratory syncytial virus (RSV) infection indicate that passive immunization by intranasal or intratracheal application of gamma-globulins (immunoglobulins) may be beneficial for treatment of infants with lower respiratory tract infection caused by RSV.


METHODS
We conducted a placebo-controlled, randomized multicenter study involving 68 infants with proven RSV infection admitted to 5 pediatric centers in Switzerland from November 1, 1992, through April 30, 1993. Treatment was carried out with aerosolized human IgG (Sandoglobulin) by assisted ventilation. On the day of hospital admission a single dose of 0.1 g of IgG per kg of body weight in a 5% solution or an identical amount of placebo, each delivered in 2 parts, was given.


RESULTS
The two groups did not differ substantially in their response to the aerosol received. The rate of improvement for symptoms of respiratory tract infection, oxygen requirement and length of hospital stay were comparable for both groups. There was a significant reduction (P < 0.05) in the frequency of apneic spells observed in the treatment group by Day 3 posttreatment. Aerosol therapy was generally well-tolerated in nonintubated infants, but some severe side effects (increased oxygen requirements in two patients, pneumothorax in one patient) were observed in two of three intubated and ventilated infants treated with IgG.


CONCLUSIONS
Aerosolized immunoglobulin in the dosage used had no substantial beneficial effect on RSV bronchiolitis. Despite these findings passive immunotherapy for treatment of RSV-induced lower respiratory tract infection deserves further evaluation before being discarded as ineffective.
Rimensberger
P C
PC
Department of Pediatrics (Inselspital), University of Berne, Switzerland.
Burek-Kozlowska
A
A
Morell
A
A
Germann
D
D
Eigenmann
A K
AK
Steiner
F
F
Burger
R
R
Kuenzli
M
M
Schaad
U B
UB
D000336:Aerosols; D000818:Animals; D000914:Antibodies, Viral / Q000494:pharmacology*; D000956:Antigens, Viral / Q000032:analysis; D002522:Chlorocebus aethiops; D006801:Humans; D007136:Immunoglobulins / Q000494:pharmacology*; D007223:Infant; D007231:Infant, Newborn; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy* / Q000276:immunology / Q000821:virology; D012136:Respiratory Syncytial Viruses / Q000145:classification / Q000187:drug effects* / Q000276:immunology / Q000302:isolation & purification; D014709:Vero Cells
D000336:Aerosols; D000914:Antibodies, Viral; D000956:Antigens, Viral; D007136:Immunoglobulins